{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:34:01Z","timestamp":1780472041359,"version":"3.54.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0396-0","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T11:16:54Z","timestamp":1445685414000},"page":"84-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1347","authenticated-orcid":false,"given":"J. Nicholas","family":"Brenton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Banwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0396-0_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/01.wnl.0000339482.84392.bd","article-title":"Incidence of acquired demyelination of the CNS in Canadian children","volume":"72","author":"Banwell","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00415-012-6441-6","article-title":"Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study","volume":"259","author":"Ketelslegers","year":"2012","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ene.12371","article-title":"Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009\u20132011)","volume":"21","author":"Reinhardt","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1352458512445944","article-title":"Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features","volume":"19","author":"Absoud","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1474-4422(11)70045-X","article-title":"Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study","volume":"10","author":"Banwell","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1177\/1352458513484377","article-title":"Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria","volume":"19","author":"Tantsis","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib8","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/brain\/awh218","article-title":"MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood","volume":"127","author":"Mikaeloff","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0396-0_bib9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1469-8749.2007.00887.x","article-title":"Early relapse risk after a first CNS inflammatory demyelination episode: examining international consensus definitions","volume":"49","author":"Dale","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/01.WNL.0000036907.37650.8E","article-title":"Course and prognosis in early-onset MS: comparison with adult-onset forms","volume":"59","author":"Simone","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-015-0396-0_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpn.2006.11.007","article-title":"Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse","volume":"11","author":"Mikaeloff","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.59.8.1224","article-title":"Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients","volume":"59","author":"Tenembaum","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-2003-42208","article-title":"Acute disseminated encephalomyelitis in children: outcome and prognosis","volume":"34","author":"Anlar","year":"2003","journal-title":"Neuropediatrics"},{"key":"10.1007\/s13311-015-0396-0_bib17","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/brain\/123.12.2407","article-title":"Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children","volume":"123","author":"Dale","year":"2000","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0396-0_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1212\/WNL.56.10.1308","article-title":"Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children","volume":"56","author":"Hynson","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/088307389501000612","article-title":"Acute disseminated encephalomyelitis: response to intravenous immunoglobulin","volume":"10","author":"Kleiman","year":"1995","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1352458508098562","article-title":"Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study","volume":"15","author":"Atzori","year":"2009","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.braindev.2014.04.013","article-title":"Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis","volume":"37","author":"Okumura","year":"2015","journal-title":"Brain Dev"},{"key":"10.1007\/s13311-015-0396-0_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0396-0_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000338630.20412.45","article-title":"Role of MRI in the differentiation of ADEM from MS in children","volume":"72","author":"Callen","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1474-4422(11)70250-2","article-title":"MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study","volume":"10","author":"Verhey","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpeds.2003.10.056","article-title":"First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability","volume":"144","author":"Mikaeloff","year":"2004","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-015-0396-0_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1212\/01.wnl.0000316193.89691.e1","article-title":"Prognostic factors after a first attack of inflammatory CNS demyelination in children","volume":"71","author":"Neuteboom","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.23575","article-title":"2010 McDonald criteria for diagnosing pediatric multiple sclerosis","volume":"72","author":"Sadaka","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib31","doi-asserted-by":"crossref","first-page":"e85741","DOI":"10.1371\/journal.pone.0085741","article-title":"Quantitative determination of regional lesion volume and distribution in children and adults with relapsing-remitting multiple sclerosis","volume":"9","author":"Ghassemi","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0396-0_bib32","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/brain\/awp278","article-title":"Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis","volume":"132","author":"Yeh","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0396-0_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.21322","article-title":"Lesion distribution in children with clinically isolated syndromes","volume":"63","author":"Ghassemi","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1212\/WNL.0b013e3182a6cb9b","article-title":"Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials","volume":"81","author":"Verhey","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1212\/01.WNL.0000152896.35341.51","article-title":"The cognitive burden of multiple sclerosis in children","volume":"64","author":"Banwell","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib37","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1212\/01.wnl.0000312276.23177.fa","article-title":"Cognitive and psychosocial features of childhood and juvenile MS","volume":"70","author":"Amato","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0883073812464816","article-title":"Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network","volume":"28","author":"Julian","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib39","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/WNL.0000000000000885","article-title":"Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib41","unstructured":"Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;(4):CD001331."},{"key":"10.1007\/s13311-015-0396-0_bib42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.41.8.1219","article-title":"Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis","volume":"41","author":"Barkhof","year":"1991","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib46","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","article-title":"A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS","volume":"73","author":"Martinelli","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib47","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/WNL.53.9.2093","article-title":"Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis","volume":"53","author":"Metz","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib49","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0887-8994(99)00042-9","article-title":"Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis","volume":"21","author":"Nishikawa","year":"1999","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/088307380401900811","article-title":"Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis","volume":"19","author":"Spalice","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib53","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.46.4.1173","article-title":"Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis","volume":"46","author":"Hahn","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib54","first-page":"211","article-title":"Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"},{"key":"10.1007\/s13311-015-0396-0_bib55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.1989.tb00031.x","article-title":"Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses","volume":"110","author":"Rossi","year":"1989","journal-title":"Immunol Rev"},{"key":"10.1007\/s13311-015-0396-0_bib56","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib57","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1212\/WNL.43.6.1100","article-title":"Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination","volume":"43","author":"Rodriguez","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib58","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.21972","article-title":"Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis","volume":"67","author":"Mowry","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib59","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/brain\/awm198","article-title":"Parental smoking at home and the risk of childhood-onset multiple sclerosis in children","volume":"130","author":"Mikaeloff","year":"2007","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0396-0_bib60","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1177\/1352458512436596","article-title":"High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women","volume":"18","author":"Hedstrom","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.0b013e31828154f3","article-title":"Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pediatrneurol.2009.03.004","article-title":"Adherence of adolescents to multiple sclerosis disease-modifying therapy","volume":"41","author":"Thannhauser","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.msard.2014.09.088","article-title":"Treatment adherence and transitioning youth in pediatric multiple sclerosis","volume":"3","author":"Lulu","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"12 Suppl. 5","key":"10.1007\/s13311-015-0396-0_bib65","first-page":"S16","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995","volume":"57","author":"Johnson","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1474-4422(05)70167-8","article-title":"Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action","volume":"4","author":"Farina","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/11588120-000000000-00000","article-title":"Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action","volume":"25","author":"Lalive","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-015-0396-0_bib68","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1191\/1352458505ms1206oa","article-title":"Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study","volume":"11","author":"Ghezzi","year":"2005","journal-title":"Mult Scler"},{"issue":"Suppl. 4","key":"10.1007\/s13311-015-0396-0_bib69","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1007\/s10072-005-0512-8","article-title":"Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study","volume":"26","author":"Ghezzi","year":"2005","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-015-0396-0_bib70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-2003-41274","article-title":"Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis","volume":"34","author":"Kornek","year":"2003","journal-title":"Neuropediatrics"},{"key":"10.1007\/s13311-015-0396-0_bib71","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review","volume":"79","author":"Lu","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-beta in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-015-0396-0_bib73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1067\/mpd.2001.117004","article-title":"Interferon-beta treatment in patients with childhood-onset multiple sclerosis","volume":"139","author":"Mikaeloff","year":"2001","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-015-0396-0_bib74","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/01.WNL.0000153570.33845.6A","article-title":"Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a","volume":"64","author":"Pohl","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib75","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/01.wnl.0000231137.24467.aa","article-title":"Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis","volume":"67","author":"Tenembaum","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib76","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1212\/01.wnl.0000198257.52512.1a","article-title":"Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis","volume":"66","author":"Banwell","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejpn.2007.08.001","article-title":"Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study","volume":"12","author":"Mikaeloff","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib78","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-015-0396-0_bib81","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jemt.1070320405","article-title":"Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis","volume":"32","author":"Aksamit","year":"1995","journal-title":"Microsc Res Tech"},{"key":"10.1007\/s13311-015-0396-0_bib82","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib83","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib84","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib85","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","article-title":"Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases","volume":"19","author":"Ghezzi","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib86","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejpn.2012.09.004","article-title":"Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis","volume":"17","author":"Arnal-Garcia","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1756285610381526","article-title":"Natalizumab in pediatric multiple sclerosis patients","volume":"3","author":"Yeh","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-015-0396-0_bib90","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archneur.65.12.1655","article-title":"Natalizumab use in pediatric multiple sclerosis","volume":"65","author":"Huppke","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib91","doi-asserted-by":"crossref","unstructured":"Ghezzi A, Moiola L, Pozzilli C, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol 2015;15:174-015-0433-y.","DOI":"10.1186\/s12883-015-0433-y"},{"key":"10.1007\/s13311-015-0396-0_bib92","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0396-0_bib93","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0396-0_bib94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1352458514549398","article-title":"Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis","volume":"21","author":"Hartung","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib95","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib96","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/1352458505ms1210oa","article-title":"A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta","volume":"11","author":"Smith","year":"2005","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib97","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00415-005-0857-1","article-title":"The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients\u2014twenty-four months follow-up","volume":"252","author":"Reggio","year":"2005","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib98","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0b013e3181a8164c","article-title":"Cyclophosphamide therapy in pediatric multiple sclerosis","volume":"72","author":"Makhani","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib99","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","article-title":"Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1179\/016164106X98099","article-title":"The B cell response in multiple sclerosis","volume":"28","author":"Owens","year":"2006","journal-title":"Neurol Res"},{"key":"10.1007\/s13311-015-0396-0_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0396-0_bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2014.02.007","article-title":"Rituximab use in pediatric central demyelinating disease","volume":"51","author":"Beres","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib104","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0396-0_bib105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib106","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib107","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clim.2011.02.017","article-title":"Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action","volume":"142","author":"Gold","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0396-0_bib109","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib111","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMc1413724","article-title":"PML in a patient without severe lymphocytopenia receiving dimethyl fumarate","volume":"372","author":"Nieuwkamp","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib112","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib113","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0396-0_bib114","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0396-0_bib115","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/1352458512450354","article-title":"Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis","volume":"18","author":"Miller","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0396-0_bib116","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0396-0_bib117","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0396-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:50:40Z","timestamp":1761807040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009418"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0396-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0396-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}